Identification of Siglec-10 as a new dendritic cell checkpoint for cervical cancer immunotherapy.

ABSTRACT:

Background

The occurrence of chronic inflammation resulting from infection with human papillomaviruses is an important factor in the development of cervical cancer (CC); thus, deciphering the crosstalk between the tumor microenvironment and innate immune cells during the establishment of immune tolerance is vital for identifying potential treatment strategies.

Methods

Single-cell RNA sequencing data and primary tumor samples from patients with CC were used to evaluate the functional role of Siglec-10 on dendritic cells (DCs). Patient-derived tumor fragment platforms were used to examine the ability of Siglec-10 blockade to reinvigorate DC-mediate T-cell activation and tumor clearance.

Results

Here, we demonstrated that Siglec-10 is a prominent inhibitory checkpoint fo

SUBMITTER: Wang C 

PROVIDER: S-EPMC11409359 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature